Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
2 Top Index Funds Growth Stock Investors Can Buy With Confidence Before 2023
01:33pm, Thursday, 08'th Dec 2022 The Motley Fool
Growth stocks have been hammered this year, but these index funds have a track record of outperformance.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:15am, Thursday, 08'th Dec 2022
The three companies are changing the pharmaceutical industry.
Relative Strength Found Within These 3 Medical Stocks
10:35pm, Monday, 05'th Dec 2022 Zacks Investment Research
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
12 Analysts Have This to Say About Eli Lilly
09:02pm, Monday, 05'th Dec 2022 Benzinga
Within the last quarter, Eli Lilly (NYSE:LLY) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
8
2
0
0
Last 30D
0
1
What 12 Analyst Ratings Have To Say About Eli Lilly
07:04pm, Monday, 05'th Dec 2022 Benzinga
Over the past 3 months, 12 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Relative Strength Found Within These 3 Medical Stocks
06:48pm, Monday, 05'th Dec 2022
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
06:03pm, Monday, 05'th Dec 2022 Zacks Investment Research
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Expert Ratings for Eli Lilly
05:06pm, Monday, 05'th Dec 2022 Benzinga
Within the last quarter, Eli Lilly (NYSE:LLY) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
8
2
0
0
Last 30D
0
1
Expect heavy market selling early next year, says Worth Charting's Carter Worth
03:01pm, Monday, 05'th Dec 2022
Carter Worth, Worth Charting CEO, joins 'The Exchange' to give the technical take on Eli Lilly and XBI.
Even After This Year's Melt-Up, Runway Remains for LLY Stock
06:15am, Monday, 05'th Dec 2022
Pharmaceutical stocks overall have fared well during this tough year for the market, but Eli Lilly (NYSE: LLY ) has been a pharma name that's truly “crushed it” so far in 2022. LLY stock has ralli
Dividend Champion, Contender, And Challenger Highlights: Week Of December 4
05:29am, Sunday, 04'th Dec 2022 Seeking Alpha
Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see companies with upcoming ex-dividend dates.
2 Unstoppable Stocks That Could Make You Richer in 2023 and Beyond
01:45pm, Friday, 02'nd Dec 2022 The Motley Fool
It would take a lot to throw these leaders off their game.
2 Healthcare Stocks That Could Help Your Portfolio
01:07pm, Friday, 02'nd Dec 2022 The Motley Fool
These two companies have each delivered market-topping total returns over the last 10 years.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
12:55pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Chinese cities announce further easing of COVID curbs, though police are still patrolling streets to stop protests
11:28am, Friday, 02'nd Dec 2022 MarketWatch
Major Chinese cities are further easing COVID restrictions, though police continue to patrol streets to avert protests.
